Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

×

This website is intended for US Healthcare Professionals

OPKO Connect provides comprehensive support

Opko Connect Graphic

Patient assistance programs

For patients identified as not having affordable access to Rayaldee therapy, OPKO offers a free drug patient assistance program; eligibility criteria apply and annual re-enrollment is required.

Copay assistance

With this program, eligible commercially insured patients can fill their Rayaldee prescription for no more than $5 per month until the annual maximum limit is reached.

Prior authorization support

Can assist with any insurer-required PAs for Rayaldee on behalf of patients.

For information on how to request
exception coverage for Medicare Part D beneficiaries please visit www.cms.gov.

OPKO Connect services are available
by phone at 844‑414‑6756
Monday through Friday, 8 AM‑8 PM ET

Click here to download a Letter of Medical Necessity for Rayaldee Click here to download the Rayaldee Service Request form